Elysium Health™ and University of Oxford Name First Prize Fellowship Recipient Who Will Study Aging and Cellular Health
NEW YORK (February 1, 2018) – Elysium Health, Inc.,™ a consumer health company developing scientifically-sound natural health products, and the University of Oxford today announced the first recipient of the Prize Fellowship to support cutting-edge research in the field of cellular health. Hanlin Zhang, a Ph.D. candidate at the University of Oxford’s Kennedy Institute of Rheumatology, will focus on characterizing a novel autophagy pathway and its impact on aging.
“Elysium Health prides itself on its pursuit of scientific breakthroughs that may have a meaningful impact on our well-being as we age,” said Dr. Leonard Guarente, co-founder and chief scientific officer at Elysium Health, who has served as the director of the Glenn Laboratory for the Science of Aging at Massachusetts Institute of Technology for the last 35 years. “We are thrilled to provide Hanlin with the Fellowship as we are confident his research will deepen our understanding of cellular health and its role in the aging process.”
Autophagy is a conserved degradation and recycling process that delivers damaged cellular components to the lysosome, a membrane-bound organelle found in all animal cells. Recent research shows that levels of autophagy are low in lymphocytes from elderly people leading to poor immune responses and thereby making the elderly more susceptible to infections. A deficiency in autophagy can also cause neurodegeneration, cancer and other age-related diseases.
“With the Prize Fellowship, I look forward to further exploring autophagy and the molecular pathways that may impact autophagy levels in the human body,” said Zhang. “I feel honored to be the first recipient, and I hope together with Elysium Health and the University of Oxford, we can gain a better understanding of the role of autophagy in the aging process.”
The Prize Fellowship includes three year’s salary, a travel stipend and financial resources to be used toward professional development. Selected fellows are expected to publish their research in scientific journals and present their findings at academic conferences. In addition, fellows are assigned a mentor from Elysium Health’s Scientific Advisory Board, which is comprised of more than two dozen of the world’s leading scientists, clinicians and industry innovators, including Nobel laureates.
“I could not be more pleased that Hanlin will be the first Prize Fellow,” said Professor Katja Simon, Kennedy Institute of Rheumatology at the University of Oxford. “I know Hanlin will increase our knowledge of the aging process and add to the growing body of research that may help advance scientific breakthroughs.”
For more information on the application process and eligibility requirements for 2018, please visit www.elysiumhealth.com.
About Elysium Health™
Elysium Health’s™ mission is to solve the biggest challenges in health with science, to help people live healthier, longer. Working directly with the world’s leading scientists and clinicians, Elysium Health™ is dedicated to translating advances in aging research and technology into effective, scientifically-sound products that help people manage their health in an actionable way. Learn more at www.elysiumhealth.com.
Victoria E. Davis